Clinical Trial Update: HARE-40: HPV Anti-CD40 RNA vaccinE [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial update for HARE-40, an HPV-targeted CD40 RNA vaccine, completed enrollment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Neoplasms
• Head and Neck Cancer
• Human Papillomavirus-related Carcinoma
• Penile Neoplasms Malignant

Drugs mentioned

• HARE-40 (HPV anti-CD40 RNA vaccine)

Snippet

Sponsor: University of Southampton | Conditions: Human Papilloma Virus Related Carcinoma, Head and Neck Neoplasm | Phase 1, Phase 2 | Status: COMPLETED